LAROTAXEL

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C45H53NO14
Molecular Weight	831.9006
Optical Activity	UNSPECIFIED
Defined Stereocenters	11 / 11
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@H]4[C@]5(C[C@H]5C[C@H]6OC[C@@]46OC(C)=O)C1=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C7=CC=CC=C7

InChI

InChIKey=DXOJIXGRFSHVKA-BZVZGCBYSA-N

InChI=1S/C45H53NO14/c1-23-29(57-39(52)33(49)32(26-15-11-9-12-16-26)46-40(53)60-41(4,5)6)21-45(54)37(58-38(51)27-17-13-10-14-18-27)35-43(36(50)34(56-24(2)47)31(23)42(45,7)8)20-28(43)19-30-44(35,22-55-30)59-25(3)48/h9-18,28-30,32-35,37,49,54H,19-22H2,1-8H3,(H,46,53)/t28-,29+,30-,32+,33-,34-,35+,37+,43-,44+,45-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C45H53NO14
Molecular Weight	831.9006
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	11 / 11
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/mesh/67531079 | https://www.cancer.gov/publications/dictionaries/cancer-drug/def/larotaxel | https://www.ncbi.nlm.nih.gov/pubmed/11472265

LAROTAXEL is a taxoid with potential antineoplastic activity. It prevents microtubule depolymerization, thereby inhibiting cell proliferation. It displays a broad spectrum of antitumor activity in vitro and in vivo, including activity against P-glycoprotein expressing tumors. LAROTAXEL was in phase III clinical trials for the treatment of breast cancer, pancreatic cancer, and bladder cancer. However, its development was discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tubulin 69 Target ID: CHEMBL2095182 Sources: Weber, G.F. (2015) Molecular Therapies of Cancer, page 117, retrieved from: https://books.google.ru/books?id=dhs_CgAAQBAJ	Activator 1447

PubMed

Title	Date	PubMed
Larotaxel: broadening the road with new taxanes.	2009-08	19604119
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy.	2008-07	18381372
Preclinical evaluation of new taxoids.	2001-09	11472265

Patents

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:20:58 GMT 2025` Edited by `admin` on `Wed Apr 02 08:20:58 GMT 2025`
Record UNII	TWQ8K8A81Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LAROTAXEL

Official Name

English

XRP-9881

Preferred Name

English

1-HYDROXY-9-OXO-5.BETA.,20-EPOXY-7.BETA.,19-CYCLOTAX-11-ENE-2.ALPHA.,4,10.BETA.,13.ALPHA.-TETRAYL 4,10-DIACETATE 2-BENZOATE 13-((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOATE)

Common Name

English

larotaxel [INN]

Common Name

English

XRP9881

Code

English

Larotaxel [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1490